Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Kolltan Pharmaceuticals raises $8.5mm in Series B round

Executive Summary

Kolltan Pharmaceuticals (oncology therapeutics start-up) has raised $8.5mm through the sale of Series B convertible preferred shares to an affiliate of private equity firm Celtic Therapeutics Holdings LLLP (lead) and Tichenor Ventures LLC. The company could add another $1.5mm to this amount should the Celtic affiliate exercise a product development option. Kolltan, founded in 2007, raised $40mm through a Series A round completed in August of last year.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies